Literature DB >> 2205273

Recent advances in understanding the pathogenesis of the hemolytic uremic syndromes.

B S Kaplan1, T G Cleary, T G Obrig.   

Abstract

One of the requirements for an agent to cause hemolytic uremic syndrome (HUS) is its ability to injure endothelial cells. Shiga-like toxin (SLT) can do this. SLT is produced by Escherichia coli and Shigella dysenteriae serotype 1; both have been implicated as causes of typical HUS. Endothelial cells have receptors (GB3) for SLT and the toxin can inhibit eukaryotic protein synthesis, thereby causing cell death. Glomerular endothelial cell injury or death results in a decreased glomerular filtration rate and many of the perturbations seen in HUS. It is no longer certain that hemolysis is the result of a microangiopathy. Cell injury results in release of von Willebrand multimers; if these are ultra-large, thrombosis may ensue. There is also increasing evidence that neutrophils have a role in the pathogenesis of typical HUS. Streptococcus pneumoniae can also cause HUS and care must be taken to avoid giving plasma to patients with S. pneumoniae-associated HUS. There is compelling evidence that types of HUS are inherited by autosomal recessive and autosomal dominant modes. Patients with autosomal recessive HUS may have recurrent episodes. Mortality and morbidity rates are high for the inherited forms.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2205273     DOI: 10.1007/bf00857676

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  84 in total

1.  Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins.

Authors:  Y Endo; K Tsurugi; T Yutsudo; Y Takeda; T Ogasawara; K Igarashi
Journal:  Eur J Biochem       Date:  1988-01-15

Review 2.  Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents.

Authors:  A J Murgo
Journal:  Semin Hematol       Date:  1987-07       Impact factor: 3.851

Review 3.  Macrophage procoagulants.

Authors:  J W Shands
Journal:  Haemostasis       Date:  1984

4.  Evidence that calpains and elastase do not produce the von Willebrand factor fragments present in normal plasma and IIA von Willebrand disease.

Authors:  S D Berkowitz; H Nozaki; K Titani; T Murachi; E F Plow; T S Zimmerman
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

5.  Purification and biological characterization of shiga toxin from Shigella dysenteriae 1.

Authors:  J E Brown; D E Griffin; S W Rothman; B P Doctor
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

6.  Vero response to a cytotoxin of Escherichia coli.

Authors:  J Konowalchuk; J I Speirs; S Stavric
Journal:  Infect Immun       Date:  1977-12       Impact factor: 3.441

7.  Disseminated intravascular coagulation in post-dysenteric haemolytic uraemic syndrome.

Authors:  K G Badami; R N Srivastava; R Kumar; A K Saraya
Journal:  Acta Paediatr Scand       Date:  1987-11

8.  Neutrophil-mediated injury to endothelial cells. Enhancement by endotoxin and essential role of neutrophil elastase.

Authors:  L A Smedly; M G Tonnesen; R A Sandhaus; C Haslett; L A Guthrie; R B Johnston; P M Henson; G S Worthen
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

9.  Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.

Authors:  J L Moake; P D McPherson
Journal:  Am J Med       Date:  1989-09       Impact factor: 4.965

10.  The cytotoxic activity of Shigella toxin. Evidence for catalytic inactivation of the 60 S ribosomal subunit.

Authors:  R Reisbig; S Olsnes; K Eiklid
Journal:  J Biol Chem       Date:  1981-08-25       Impact factor: 5.157

View more
  32 in total

1.  Escherichia coli O157:H7, other verotoxin-producing E coli and the hemolytic uremic syndrome in childhood.

Authors:  P C Rowe
Journal:  Can J Infect Dis       Date:  1995-03

2.  A plea for standardized terminology within the haemolytic uraemic syndromes.

Authors:  C M Taylor; D V Milford; R H White
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714

3.  Shiga toxin 2 and lipopolysaccharide induce human microvascular endothelial cells to release chemokines and factors that stimulate platelet function.

Authors:  Fadila Guessous; Marek Marcinkiewicz; Renata Polanowska-Grabowska; Sudawadee Kongkhum; Daniel Heatherly; Tom Obrig; Adrian R L Gear
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

4.  Characterization of verocytotoxin-producing Escherichia coli O157 isolates from patients with haemolytic uraemic syndrome in Western Europe.

Authors:  A E Heuvelink; N C van de Kar; J F Meis; L A Monnens; W J Melchers
Journal:  Epidemiol Infect       Date:  1995-08       Impact factor: 2.451

5.  Shiga toxin-associated hemolytic uremic syndrome: combined cytotoxic effects of shiga toxin and lipopolysaccharide (endotoxin) on human vascular endothelial cells in vitro.

Authors:  C B Louise; T G Obrig
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

6.  Shiga toxin-associated hemolytic-uremic syndrome: combined cytotoxic effects of Shiga toxin, interleukin-1 beta, and tumor necrosis factor alpha on human vascular endothelial cells in vitro.

Authors:  C B Louise; T G Obrig
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

7.  Elevated levels of vascular endothelial growth factor in serum of patients with D+ HUS.

Authors:  D Maroeska Te Loo; Nienke Bosma; Victor Van Hinsbergh; Paul Span; Rob De Waal; Ruud Clarijs; C Sweep; Leo Monnens; Lambertus Van Den Heuvel
Journal:  Pediatr Nephrol       Date:  2004-05-13       Impact factor: 3.714

8.  Hemolytic uremic syndrome induced by lipopolysaccharide and Shiga-like toxin.

Authors:  Masahiro Ikeda; Shuichi Ito; Masataka Honda
Journal:  Pediatr Nephrol       Date:  2004-03-09       Impact factor: 3.714

9.  Shiga toxin-associated hemolytic uremic syndrome: interleukin-1 beta enhancement of Shiga toxin cytotoxicity toward human vascular endothelial cells in vitro.

Authors:  S A Kaye; C B Louise; B Boyd; C A Lingwood; T G Obrig
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

10.  Identification of a clone of Escherichia coli O103:H2 as a potential agent of hemolytic-uremic syndrome in France.

Authors:  P Mariani-Kurkdjian; E Denamur; A Milon; B Picard; H Cave; N Lambert-Zechovsky; C Loirat; P Goullet; P J Sansonetti; J Elion
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.